Turning
complex biology into medicines
GeN Ltd combines human disease biology and tailored preclinical platforms to identify and advance new therapeutic opportunities for rare neurological disorders.
RARE DISEASE DRUG DISCOVERY
From prediction to preclinical proof
A focused asset story for pharmaceutical partners seeking rare-disease opportunities with experimental evidence.
Discover
Guided disease–compound prioritisation
Advance
Programmes for licensing or co-development
